Feb 28 |
Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...
|
Feb 28 |
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Immunocore GAAP EPS of -$0.40 misses by $0.13, revenue of $70.16M beats by $1.79M
|
Feb 28 |
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
|
Feb 27 |
Immunocore FY 2023 Earnings Preview
|
Feb 22 |
Immunocore to work with Bristol on combination melanoma therapy trial
|
Feb 22 |
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
|
Feb 21 |
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
|
Feb 19 |
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
|
Feb 14 |
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
|